Kalehua Capital Management
Mentions in press and media 4
| Date | Title | Description |
| 12.08.2026 | Vaderis Therapeutics Secures $152M to Advance HHT Treatment | Vaderis Therapeutics secured $152 million in Series B funding. This landmark investment propels engasertib, a potential first treatment for rare Hereditary Hemorrhagic Telangiectasia (HHT), into global Phase 3 trials. HHT causes severe nose... |
| 11.08.2026 | EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing | EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing Tue, Aug 11, 2026 13:00 CET Report this content EQT Life Sciences is investing USD 17.5 million in Vaderis Therapeutics as part of the Swiss company'... |
| 11.08.2026 | Vaderis Therapeutics Raises $152M in Series B Funding | Vaderis Therapeutics, a Basel, Switzerland-based provider of targeted therapies for rare vascular diseases, raised $152M in Series B funding. The round was led by Life Sciences at Goldman Sachs Alternatives and TCGX with participation from ... |
| 11.08.2026 | Vaderis Therapeutics closes USD 152 million Series B Financing | Together, Vaderis Therapeutics' two milestones mark a significant step forward in the development of engasertib, an investigational oral allosteric AKT inhibitor. Engasertib is positioned to become the first approved therapy specifically d... |